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Hepatic arterial cannulation for regional chemotherapy
is safe in patients with a liver metastasis volume of
less than I litre
D Burke, C Fordy, SA Earlam and TG Allen-Mersh
Department of Surgery, Charing Cross and Westminster Medical School, Chelsea and Westminster Hospital, London, UK
Summary Hepatic arterial cannulation for regional chemotherapy was achieved in 121/134 (90.2%) of colorectal liver metastasis patients.
The perioperative mortality (5.8%) was significantly greater (P= 0.004) in patients with > 1000 ml (5/22, 23%) compared with < 1000 ml (2/83,
2.4%) metastasis volume. Colorectal liver metastasis patients should be considered for regional chemotherapy before metastases become
extensive.
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Metastasis resection cures 5% of patients with colorectal liver
metastases (Steele and Ravikumar, 1989) but for the rest, tumour
growth produces abdominal pain and distension, jaundice and
inferior venacaval compression, resulting in death at an average of
7 months from liver metastasis diagnosis (Wood, 1980; Allen-
Mersh et al, 1994). Continuous hepatic arterial floxuridine infu-
sion prevents clinically significant liver metastasis growth in 70%
of patients (Dworkin and Allen-Mersh 1991; Allen-Mersh et al,
1994), and doubles survival compared with patients receiving
symptom palliation (Piedbois et al, 1996). Although the hepatic
artery can be cannulated percutaneously by inserting a Seldinger
wire via the axillary or femoral artery under fluoroscopy, long-
term treatment has not been possible with this approach because of
catheter dislodgement and misperfusion of adjacent structures
(Cohen et al, 1983). These difficulties can be avoided by direct
insertion of the catheter at laparotomy, but the limited survival
benefit of hepatic arterial floxuridine could be impaired by
complications from open hepatic artery cannulation.
This study assessed the morbidity and mortality in colorectal
liver metastasis patients undergoing hepatic arterial cannulation at
laparotomy and identified patient- or disease-related characteris-
tics that were associated with a complicated outcome.
MATERIALS AND METHODS
All colorectal liver metastasis patients undergoing hepatic arterial
cannulation in one unitbetween March 1988 andJanuary 1996 were
assessed. All had unresectable liver metastases with no evidence of
extrahepatic disease after primary tumour removal, on abdominal
computerized tomography (CT) scan and chest radiograph.
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Exclusion criteria were patient age > 75 years, Karnofsky perfor-
mance < 60, serum bilirubin > 20 mmol 1-1 or ascites.
Liver metastasis volume was measured from CT scan (Dworkin
et al, 1995a). Any weight loss in the month before hepatic artery
cannulation was noted. Serum liver function tests, albumin,
creatinine and full blood count were measured before and after
operation. Physical symptoms were assessed by the Rotterdam
Symptom Checklist (De Haes et al, 1990) before and at monthly
intervals after operation.
At laparotomy via a subcostal incision, an Infusaid (Infusaid,
Norwood, MA, USA) arterial cannula was inserted into the gastro-
duodenal artery to lie at its junction with the common hepatic
artery (Curley et al, 1993). Additional arteries were ligated where
there was aberranthepatic arterial anatomy (Burke et al, 1995). All
operations were performed by one consultant surgeon. On the fifth
post-operative day, patients commenced floxuridine (0.2 mg kg-'
body weightday-') by continuous hepatic arterial infusion for a 14-
day cycle that was repeated each month (Allen-Mersh et al, 1994).
Assessment of the duration of hospital stay excluded patients
dying in hospital within 30 days ofoperation.
RESULTS
A total of 134 colorectal liver metastasis patients underwent
laparotomy for hepatic arterial cannulation.
Failed cannulation group
Thirteen patients (9.7%) underwent laparotomy without hepatic
artery cannulation. Liver metastasis volume was significantly
greater (MWU test, P = 0.012) in failed cannulation (median
1970 ml, interquartile range 643-3018 ml) compared with cannula-
tion (374 ml, interquartile range 66-1000 ml) patients. Reasons for
failed cannulation were inaccessibility of the hepatic artery owing
to gross hepatic enlargement (five patients) or hepatic arterial
encasement by involved hepatic nodes (eight patients). Twelve of
these patients underwent portal vein cannulation via a mesenteric
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Figure 1 Seven patients (5.9% of successful cannulations), of whom five died within 30 days of operation, developed significant (P < 0.05 Mann-Whitney
U-test) tachycardia, hypotension, liver and renal function abnormalities and thrombocytopenia, but not leucocytosis, within 3 days of surgery. Closed symbols,
affected patients; open symbols, non-affected patients
vein and no procedure was performed in the thirteenth patient.
There were no perioperative deaths.
Cannulation group
A total of 121 patients (median age 59 years, interquartile range
48-67 ml; median liver metastasis volume 374 ml, interquartile
range 66-1000 ml) underwent hepatic artery cannulation. The
hospital stay for cannulation was not significantly longer (MWU
test, P = 0.15) in patients with > 1000 ml (median 13 days,
interquartile range 11-14 days) compared with < 1000 ml (median
12 days, interquartile range 9-16 days) liver metastasis volume.
Perioperative mortality
There were seven deaths within 30 days (post-operative days 1, 1,
5, 5, 7, 11 and 22) of operation (perioperative mortality 5.8%).
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Table 1 Perioperative morbidity and mortality by patient- and disease-related
preoperative factors
30-day incidence (%)
Variable at liver Death P Complications P
metastasis diagnosis (n = 7) Fisher's (n = 10) Fisher's
exact exact
Weight loss
No (n = 81) 3 (3.7) 7 (8.6)
NS NS
Yes (n = 33) 4 (12.0) 3 (9.0)
Serum albumin
<30 g dl-' (n = 17) 3(17.6) 5 (29.0)
NS NS
>30 g dl-' (n = 70) 1 (1.4) 3 (4.3)
Alkaline phosphatase
< 300 IU (n = 52) 1 (1.9) 4 (7.7)
NS NS
> 300 IU (n = 47) 5 (10.6) 6 (12.8)
Karnofsky
<90(n=16) 3(18.8) 2(12.5)
NS NS
> 90 (n = 100) 4 (4.0) 8 (8.0)
Tumour volume
< 1000 ml (n = 83) 2 (2.4) 9 (10.8)
0.01 NS
> 1000 ml (n = 22) 5 (22.7) 1 (4.5)
There was a significant increase (P= 0.01, Fisher's test) in the incidence
of death but not complications within 30 days of hepatic artery cannulation
in patients whose liver metastasis volume was > 1000 ml compared with
< 1000 ml. Other variables at diagnosis of liver metastasis did not predict for
either perioperative death or complications.
Five were in patients with > 1000 ml tumour volume who exhib-
ited a syndrome of tachycardia, thrombocytopenia and liver and
renal failure by the third post-operative day (Figure 1). The sixth
patient (tumour volume 907 ml) died on the first post-operative
night following hepatic arterial rupture that was thought to be
caused by catheterization-induced intimal tear. The seventh patient
(tumour volume 418 ml) died on the second post-operative night
following an acute myocardial infarction.
There was a significant increase (Fisher's test, P = 0.004) in
perioperative mortality in patients with > 1000 ml metastasis
volume (5/22, 23%) compared with < 1000 ml (2/83, 2.4%).
Stratification by preoperative history of weight loss, serum
albumin, serum alkaline phosphatase orperformance status did not
significantly identify high risk ofperioperative death (Table 1).
Morbidity
Ten patients (8.2%) developed post-operative complications:
[tachycardia/thrombocytopenia/liver and renal function abnor-
malities (as in Figure 1), two; pneumonia, two; pump pocket infec-
tion, two; subphrenic abscess, one; pyrexia ofunknown origin, one;
pump pocket haematoma, one; and pseudomembranous colitis,
one]. Thepost-operative stay was significantly longer(MWU test, P
= 0.003) in complicated (median 19 days, interquartile range 11-34
days) compared with uncomplicated (median 12 days, interquartile
range 9-15 days) patients. There was no significant difference in
preoperative tumour volume, serum albumin, serum alkaline phos-
phatase, weight loss or performance status in patients developing
complications compared with those who did not (Table 1).
Significant deterioration in Rotterdam Symptom Checklist
physical symptom score was not detected between preoperative
baseline and that during the first 3 post-operative months.
DISCUSSION
The perioperative mortality ofopen hepatic arterial cannulation in
this study (5.8%) would have been reduced to 2.4%, if patients
with > 1000 ml tumour volume (roughly 40% liver replacement)
had been excluded. Although 50% ofpatients can expect a partial
tumour response from hepatic arterial floxuridine (Dworkin et al,
1991) regardless of extent of disease, the higher perioperative
mortality (23% vs 2.4%) and failed cannulation (27% vs 8.4%)
rate in patients with more than compared with less than 1000 ml
liver metastasis volume resulted in 39% ofpatients with extensive
metastases either failing to have the hepatic artery cannulated or
dying within a month of the procedure. The absence of a signifi-
cant increase in morbidity in patients with > 1000 ml liver meta-
stasis volume (Table 1) compared with < 1000 ml may have been
because post-operative complications in patients with extensive
disease were more likely to result in death than complications.
Campbell et al (1993) have previously shown that both compli-
cations and successful liver infusion depend on operator experi-
ence with open hepatic artery cannulation. The technique can be
difficult where the liver is greatly enlarged by metastases, or the
hepatic artery encased by involved nodes, or where there are aber-
rant hepatic arteries (Burke et al, 1995). Cannulation was not
possible in 9.7% of our patients. Six of the 13 patients whose
hepatic artery could not be cannulated would have avoided a
laparotomy, if patients with > 1000 ml tumour volume had been
excluded. The remaining seven (5.2% ofall patients) could not be
cannulated because of hepatic arterial encasement by involved
nodes. This non-cannulation rate is lower than in aprevious report
(Chang et al, 1987) in which any hepatic node involvement at
laparotomy was taken as a contraindication to hepatic arterial
chemotherapy. A sensitive predictor that hepatic nodes will not
be involved with disease is a node-negative primary colorectal
tumour (Dworkin et al, 1995b) but this has a low specificity, as
hepatic nodes are uninvolved by liver metastases in 64% ofnode-
positive primary colorectal cancers. We have not found that CT
scan predicts hepatic artery encasement by involved nodes, and
there is no reliable non-invasive test of hepatic lymph node
involvement.
The cause of the tachycardia, thrombocytopenia and liver and
renal function abnormalities that preceded the deaths of five
patients and occurred in two other patients with extensive meta-
stases was not clear. The features were consistent with an acute
sepsis syndrome (Dunn, 1994), but there was no evidence ofinfec-
tion on blood culture or at autopsy. In addition, the post-operative
white cell count was not significantly different in these patients
compared with uncomplicated cases (Figure 1). These abnormali-
ties might have been produced by release of inflammatory media-
tors from liver parenchyma (Jenkins and Williams, 1980) or liver
metastases (Ueda et al, 1994). Hepatic parenchymal volume is not
reduced by colorectal liver metastases (Dworkin et al, 1995a), and
it is also possible that catheterization-induced hepatic arterial
thrombosis resulted in parenchymal necrosis where portal venous
flow was impeded by metastases (Martin et al, 1990).
The median tumour volume at which metachronous colorectal
liver metastases are diagnosed clinically is approximately 800 ml
(Allen-Mersh et al, 1994). Thus, if liver metastasis diagnosis after
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primary tumour resection relies on clinical examination, the
interval between detection ofmetastases andunsuitability foropen
hepatic artery cannulation is less than one tumour volume
doubling time (Allen-Mersh, 1991). Patients at high risk of liver
metastases, who are deemed potentially suitable for intrahepatic
chemotherapy, should undergo regular liver imaging (Gunven et
al, 1985) so that metastases are detected before symptoms and
signs develop. This would offer the best opportunity both for
metastasis resection (Steele and Ravikumar, 1989) and also for
uncomplicated hepatic arterial cannulation to administer regional
chemotherapy.
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